Alembic Pharma Q2 FY27 Consolidated Revenue Up 36% to ₹2,603 Crore, Profit Jumps 81%
Alembic Pharmaceuticals reported a 36% year-on-year increase in consolidated total income to ₹2,603.48 crore for Q2 FY27. Consolidated net profit after tax surged 81% to ₹335.17 crore. Standalone income rose to ₹2,391.65 crore with net profit after tax at ₹409.36 crore.
The substantial increase in revenue and profit is a material event that is likely to have a significant positive impact on the company's stock performance and investor sentiment.
The company reported significant year-on-year growth in both revenue and profit for the quarter, indicating strong financial performance.
Alembic Pharmaceuticals Limited announced its financial results for the quarter ended September 30, 2026. The company reported a consolidated total income from operations of ₹2,603.48 crore, a significant increase from ₹1,910.15 crore in the same quarter last year. Consolidated net profit after tax attributable to shareholders surged by 81% to ₹335.17 crore, compared to ₹184.71 crore in the corresponding quarter of the previous fiscal year.
The standalone total income from operations also saw a substantial rise to ₹2,391.65 crore from ₹1,796.24 crore in the quarter ended September 30, 2025. Standalone net profit after tax increased to ₹409.36 crore from ₹179.36 crore in the year-ago period.
The company's financial results for the quarter were approved by the Board of Directors on November 4, 2026. Detailed financial results are available on the websites of the Stock Exchanges and the company.
What to do with a filing like this
Alembic Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alembic Pharmaceuticals Limited. Read the original for the full detail.